A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

Inclusion Criteria: * Provision of informed consent prior to any study specific procedures * Female or male aged ≥18 years * History of type 2 diabetes mellitus for more than 12 months * HbA1c≥7.0% and ≤11.0% * Stable antidiabetic treatment during the last 12 weeks up to randomization * eGFR 25-75 mL/minute/1.73m2, inclusive * Micro or macroalbuminuria (UACR 30 - 3500 mg/g) * Treatment with ACE inhibitor or an ARB for at least 3 months prior to screening * Body mass index between 20 and 45 kg/m2 Exclusion Criteria: * Any of the following CV/Vascular Diseases within 3 month prior to signing the consent at Visit 1: * Myocardial infarction * cardiac surgery or revascularization (CABG/PTCA) * unstable angina * unstable HF * New York Heart Association (NYHA) Class III-IV * transient ischemic attack (TIA) or significant cerebrovascular disease * unstable or previously undiagnosed arrhythmia * Significant hepatic disease, including, but not limited to, chronic active hepatitis and/or severe hepatic insufficiency * Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) \> 3X ULN * Total Bilirubin (TB) \>2 mg/dL (34.2 μmol/L) * History of acute kidney injury requiring renal replacement therapy (dialysis or ultrafiltration) or any biopsy or imaging verifying intercurrent kidney disease other than diabetic nephropathy or diabetic nephropathy with nephrosclerosis * Ongoing treatment with a SGLT2 inhibitor, GLP-1 agonist or DPP4 inhibitors * Any condition which, in the judgment of the Investigator, may render the patient unable to complete the study or which may pose a significant risk to the patient or patient suspected or with confirmed poor protocol or medication compliance